These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2006-006599-39 An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus 2008-07-14 due-trials
Not reported 2006-006600-11 An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus 2008-07-07 due-trials
Not reported 2007-006084-73 An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAjectTM in Subjects with Type 1 Diabetes Mellitus 2010-01-19 due-trials
Not reported 2007-006085-15 An Open Label, Multi-Center, Follow-on Study Examining the Long- Term Safety and Efficacy of Insulin VIAject™ in Subjects with Type 2 Diabetes Mellitus 2010-01-13 due-trials
Not reported 2008-001184-11 Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patients 2008-08-01 due-trials
Completed, report not yet due 2008-001670-32 A Single-Center, Double Blind Study Evaluating the Bioequivalence of the Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of VIAject™ in Subjects with Type 1 Diabetes Mellitus 2008-12-21 not-yet-due
Completed, report not yet due 2009-012082-54 A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject... 2009-09-15 not-yet-due
Not reported 2009-013264-39 A Single-Center, Double Blind, Randomized Crossover Study Evaluating Injection Site Toleration of VIAject® 7, VIAject® 25 and Insulin Lispro in Subjects with Type 1 or Type 2 Diabetes Mellitus 2009-11-13 due-trials